Some GLP-1 receptor agonists may hold promise as treatments for alcohol use disorder (AUD), a Swedish observational study ...

In addition to ensuring equitable access to the glucagon-like peptide-1 (GLP-1) receptor agonists, the medical community ...

As the FDA issues a new warning about aspiration across all GLP-1 weight loss drugs, doctor groups are giving new ...

Labels of all GLP-1 receptor agonists now carry a warning about pulmonary aspiration during general anesthesia or deep ...

Poor bowel preparation also led to repeat colonoscopies for 18.9% of current GLP-1RA users, compared to 11.1% of controls ...

Recent studies have shown that pharmacological treatment with GLP-1-RA and dual GLP-1/glucose-dependent insulinotropic ...

In an analysis of more than 7,000 stroke survivors, those who were taking either a GLP1-receptor agonist or an SGLT2 ...

The FDA has updated the labels for all GLP-1 receptor agonists, including popular medications Ozempic, Wegovy, Saxenda and Mounjaro, to include a new warning about the risk of pulmonary aspiration ...

Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) can decrease the risk for developing early-onset colorectal cancer (EO-CRC) in patients with diabetes regardless of weight, according to a ...

Novo Nordisk has signed off on a $285 million biobucks deal with fellow Denmark-based company Ascendis Pharma to help the Wegovy manufacturer develop a once-monthly GLP-1 receptor agonist.

GLP-1 receptor agonists, originally developed for managing type 2 diabetes, have rapidly emerged as highly effective ...